All In Biotech

Drug Trial Radar · NCT07421167

A Study to Assess the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP)

A Phase 2 Open-label Study to Evaluate the Tolerability of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least One Treatment (VAY2EXPLORE)

Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 164 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

164

Planned (sponsor's estimate)

Start

Aug 4, 2026

Primary completion

Jan 18, 2029

Study completion Aug 31, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Feb 19, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate the tolerability of ianalumab (9 mg/kg) with investigator's choice thrombopoietin receptor agonist (IC TPO-RA) in participants diagnosed with primary immune thrombocytopenia (ITP) who have been treated with at least one but no more than four prior treatments, and with no change in IC TPO-RA dose in at least the last 14 days prior to the start of ianalumab.

Conditions

  • Primary Immune Thrombocytopenia (ITP)
  • Primary Evans Syndrome (ES)

Interventions

  • ianalumabBiological

    9 mg per kilogram infusion every 4 weeks (Q4W) for 16 weeks

  • thrombopoietin receptor agonist (TPO-RA)Drug

    IC TPO-RAs will be administered according to the respective United States Prescribing Information (USPIs)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. (Main cohort: Primary immune thrombocytopenia (ITP)): Percentages of participants who are tolerable to ianalumab (9 mg/kg)Time frame: Up to Week 16

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Ironwood Cancer and Research Centers

    Chandler, Arizona · Recruiting

  • Highlands Oncology Group

    Fayetteville, Arkansas · Recruiting

  • Harbor-UCLA Medical Center

    Torrance, California · Recruiting

  • Lutheran Hospital Cancer Centers

    Golden, Colorado · Recruiting

  • Yale Cancer Center

    New Haven, Connecticut · Recruiting

  • Stamford Hospital

    Stamford, Connecticut · Recruiting

  • Baptist MD Anderson Cancer Center

    Jacksonville, Florida · Recruiting

  • DH Cancer Research Center LLC

    Margate, Florida · Recruiting

  • University Of Miami

    Miami, Florida · Recruiting

  • Advent Health Orlando

    Orlando, Florida · Recruiting

  • Hope And Healing Care

    Hinsdale, Illinois · Recruiting

  • Pontchartrain Cancer Center

    Covington, Louisiana · Recruiting

  • Mayo Clinic Rochester

    Rochester, Minnesota · Recruiting

  • University Health Kansas City

    Kansas City, Missouri · Recruiting

  • Intermountain Healthcare

    Billings, Montana · Recruiting

  • Astera Cancer Center

    East Brunswick, New Jersey · Recruiting

  • Summit Medical Group

    Summit, New Jersey · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • Hospital of the University of Pennsylvania Health System

    Philadelphia, Pennsylvania · Recruiting

  • Western Pennsylvania Hospital

    Pittsburgh, Pennsylvania · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • JPS health Network

    Fort Worth, Texas · Recruiting

  • Utah Cancer Specialists

    Salt Lake City, Utah · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.